Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma

### Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma

Expert

We at Advanced Medicine In China are proud to have Professor Qiu Luguo as our contracted expert. He provides telemedicine consultations for our international patients and can arrange for them to travel to China through a special fast-track system. Patients can receive treatment in the hospital where Professor Qiu works, under his direct supervision as their attending physician, ensuring comprehensive and professional care throughout the treatment process.

Professor Qiu is renowned in the field of hematologic oncology, particularly for treating patients who have not responded well to standard therapies. His deep expertise and innovative treatment approaches have brought new hope to patients, especially those with complex conditions. Through our services, international patients can not only access cutting-edge treatment recommendations via telemedicine but also come to China to receive the most advanced medical care.

The process is straightforward and efficient. Patients only need to submit the following documents, and our team will assist in arranging everything from teleconsultation to full treatment in China:

1. Pathology report

2. Latest discharge summary

3. Detailed description of the condition

4. History of treatment and its effectiveness

We recommend Professor Qiu for his exceptional achievements and extensive experience, which have provided a wide range of treatment options for countless hematologic cancer patients. His international reputation further affirms his outstanding contributions to the fields of hematology and multiple myeloma.

### Expert Profile

Professor Qiu Luguo is the Director of the Lymphoma Diagnosis and Treatment Center at the Hematology Hospital, Chinese Academy of Medical Sciences, and Director of the Tianjin Cord Blood Hematopoietic Stem Cell Bank. He has long been dedicated to both clinical and basic research in hematologic diseases. Professor Qiu is a recipient of the State Council’s special government allowance and has been recognized as an Outstanding Young and Middle-aged Expert by the National Health Commission of China. As a leading authority in lymphoma and multiple myeloma treatment, he is also a member of several international academic organizations, including the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG).

### Areas of Expertise

Professor Qiu is highly skilled in the diagnosis and treatment of lymphatic system tumors, particularly in the precise diagnosis, stratified treatment, and prognosis evaluation of lymphoma, chronic lymphocytic leukemia, and multiple myeloma. He has also made significant progress in the application of hematopoietic stem cell transplantation technology, offering new treatment options for patients with hematologic diseases.

### Research Contributions and International Recognition

Throughout his 30-plus-year career, Professor Qiu has completed more than 30 national research projects and published nearly 700 papers in leading academic journals, with over 160 of them in SCI-indexed journals. His research achievements have garnered widespread attention in China and have been highly regarded in the international hematology community. He has been invited to speak at numerous international conferences and actively promotes global academic collaboration and exchange.

### Major Research Directions

Professor Qiu’s research focuses on the pathogenesis and precision treatment strategies for lymphatic system tumors. His work spans a broad range of fields, from basic research to clinical applications, covering the diagnosis, prognosis, and personalized treatment of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Additionally, he has conducted in-depth studies on hematopoietic stem cell transplantation and stem cell engineering, striving to develop innovative therapies that improve patient cure rates.

### Publications and Scientific Achievements

Professor Qiu has authored five major medical books, holds five national invention patents, and has received multiple first-place awards for his scientific achievements in China. His groundbreaking work in the genomics of multiple myeloma and chronic lymphocytic leukemia has made significant progress in early diagnosis and targeted treatment of these diseases. His research has not only advanced the treatment of lymphatic system tumors but also set an example for young researchers in the field of hematology.

With his exceptional clinical and research accomplishments, Professor Qiu Luguo has become a key figure in the global hematology community. His contributions have not only brought hope to patients but also laid a solid foundation for future advancements in the treatment of blood diseases. Some of his major publications include:…

1. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283. (IF: 19.456)

2. Indirubin-3′-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. E Bio Medicine. 2022 Apr;78:103950. (IF:11.205)

3. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. (IF: 12.531)

4. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021 May 27;137(21):2890-2901. (IF: 22.133)

5. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021 Aug;35(8):2412-2415. Jan 22. (IF:12.883)

6. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020，136(4):468-479. (IF:16.509)

7. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020,34(2):578-588. (IF:11.528)

8. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018,128(7):2877-2893. (IF:12.87)

9. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017.31(5):123-1135. (IF:11.412)

10. Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med.19(2):182-191. (IF:7.756)

### Online Consultation and Appointment Information

Professor Ke currently offers online video consultation services. Patients can make appointments through the following methods:

WhatsApp: Https://wa.me/+8613717959070 

Wechat：doctors0152

Email: doctor.huang@globecancer.com

#HematologyExpert #MultipleMyeloma #LymphomaTreatment #BloodCancer #StemCellTransplantation #MedicalInnovation #Telemedicine #InternationalHealthcare #AdvancedMedicineInChina #PrecisionMedicine #ProfessorQiuLuguo #CancerResearch #GlobalHealth #PatientCare #Oncology

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago CAR-T

At which stage of treatment is the best time to choose CAR-T therapy?

At which stage of treatment is the best time to choose CAR-T therapy?

CAR-T therapy is often used as a last resort, but it should be introduced earlier for better outcomes. Early use, even as a frontline or 1.5-line treatment, could dramatically increase patient cure rates.

Tumor cells are highly adaptable and intelligent, learning to evade treatments over time. Treating tumors early, before they become stronger, is crucial.

CAR-T should not be considered a “last resort” in treatment, as waiting too long may reduce its effectiveness. It’s better to “kill the tumor when it’s young” before it becomes more resilient and difficult to eliminate.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago CAR-T

**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**

**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**

As an innovative immunotherapy, CAR-T therapy has gradually become available in China in recent years, attracting significant attention from patients. Although it is dubbed the “million-dollar therapy” due to its high cost, experts emphasize that CAR-T is not a conventional drug but a “living drug.” Its effectiveness is confirmed, but the outcome largely depends on the skill and experience of the operator. Like a horse-riding competition, the handler must fully understand and control this “good horse.” Early data show promising results, and while the overall treatment cost remains high, its efficacy is undeniable.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago patient story

**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**

**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**

patient story

In the long journey of life, cancer often strikes like a sudden storm, leaving patients and their families devastated. Mrs. Li, a young and resilient mother from China, was no exception. Two years ago, she was diagnosed with relapsed and refractory B-cell non-Hodgkin lymphoma. The shocking news felt like a bolt from the blue, throwing her once-happy family into the depths of despair.

Traditional chemotherapy and radiation therapy once brought a flicker of hope for Mrs. Li, temporarily alleviating her condition. However, fate seemed to play a cruel trick on her again, as the tumor returned with more aggression, no longer responding to conventional treatments. The repeated rounds of therapy took a toll on her body and spirit. Both Mrs. Li and her family were pushed to the brink of collapse, feeling trapped in a deep abyss with no light of hope in sight.

Just when Mrs. Li was about to give up, fate intervened. Thanks to the relentless efforts of the “Advanced Medicine in China” team, they successfully connected Mrs. Li with the country’s top hematology specialists. After a series of communications and coordination, this expert became her last lifeline, taking on the responsibility of devising the best treatment plan during her darkest hours.

After conducting a comprehensive and detailed examination of Mrs. Li, the expert, relying on extensive experience and professional judgment, decisively recommended CAR-T therapy, a cutting-edge treatment. This innovative immunotherapy acts like a magical key, reactivating the patient’s immune system to precisely target and attack cancer cells, offering a new glimmer of life. Faced with this final hope, Mrs. Li carefully considered her options and bravely decided to seize it, determined to fight once more for her life.

The results were truly remarkable. CAR-T therapy produced astonishing effects in Mrs. Li, like a dazzling light in the darkness. After just a few weeks, follow-up tests showed that her tumor had significantly shrunk, and the symptoms that had once plagued her improved dramatically. This was a pivotal moment, allowing Mrs. Li and her family to rediscover hope for the future.

In the months that followed, under close monitoring and consolidation treatment, Mrs. Li’s condition stabilized, as though the ferocious beast of cancer had been tamed. Ultimately, she achieved a miracle—her cancer reached complete remission. For Mrs. Li and her family, this was nothing short of extraordinary, filling their hearts with overwhelming joy and gratitude. They were not only rekindled with the flame of hope for life but also deeply thankful to the “Advanced Medicine in China” team and CAR-T therapy.

As the recommending team, “Advanced Medicine in China” feels honored to have witnessed Mrs. Li’s recovery journey. This is not just a victory for one patient but a successful step forward in the ongoing battle against cancer, inspiring the team to continue seeking rays of hope for more patients. Mrs. Li’s story has become a powerful tale of triumph, spreading rapidly among fellow patients. Her courage and perseverance have set an example for many others bravely fighting blood cancer, encouraging them to press on and never give up.

Through Mrs. Li’s case, CAR-T therapy in China has once again demonstrated its immense potential in the treatment of lymphoma. Like a rising star, it is bringing new hope to blood cancer patients worldwide, illuminating their path toward overcoming the disease. In the future, CAR-T therapy in China will undoubtedly create more miracles, offering patients the dawn of life and a brighter future.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#patientstory #CARTTherapy #CancerSurvivor #Lymphoma #LymphomaTreatment #BloodCancerAwareness#MedicalMiracles #ChinasMedicalAdvances #CancerResearch #PatientStories #HopeAgainstCancer #Immunotherapy #FightCancer #CancerRemission #CourageToFight #BreakthroughInMedicine

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Hematological Neoplasms

Blood Cancer – Diagnosis and Treatment Tips

Blood Cancer – Diagnosis and Treatment Tips

#leukemia #multiplemyeloma #lymphoma

Blood Cancer

Blood cancer, encompassing types such as leukemia, lymphoma, and multiple myeloma, represents a significant health challenge in regions like Southeast Asia and India. These hematologic malignancies arise from blood-forming cells and can impact the bone marrow, blood, and various organs. The increasing prevalence of these diseases is concerning, yet advancements in diagnosis and treatment provide hope for patients.

## Understanding Hematologic Malignancies

Hematologic malignancies include a variety of cancers such as:

– **Leukemia**: Cancer of the bone marrow that leads to the overproduction of abnormal white blood cells.

– **Lymphoma**: Affects the lymphatic system and includes #Hodgkin and #nonHodgkinlymphoma.

– **Multiple Myeloma**: Cancer that forms in plasma cells, affecting the production of antibodies.

The causes of these conditions are multifactorial, involving genetic factors, immune dysfunction, exposure to environmental toxins, and lifestyle choices. For instance, a diet high in processed foods, sedentary behavior, and high stress levels can contribute to an increased risk of developing these cancers.

## The Rising Incidence of Blood Cancer

The incidence of blood cancers is on the rise globally, particularly in countries with aging populations. In Southeast Asia and India, there has been a noticeable increase in cases of leukemia and lymphoma, necessitating better awareness and improved healthcare infrastructure.

## Diagnosis: Early Detection is Key

Early diagnosis is crucial for successful treatment outcomes. Patients experiencing symptoms such as unexplained fatigue, frequent infections, easy bruising, or swollen lymph nodes should seek medical advice promptly. Healthcare providers may utilize blood tests, bone marrow biopsies, and imaging studies to diagnose these conditions accurately.

## Treatment Advances: A Diverse Approach

Recent years have seen significant advancements in the treatment of hematologic malignancies, offering patients more options than ever before:

1. **Combination Chemotherapy**: Despite potential side effects, combination chemotherapy remains a cornerstone treatment. New regimens are being developed that combine traditional cytotoxic drugs with targeted therapies and immunotherapies to enhance efficacy and reduce toxicity.

2. **Targeted Therapies**: Drugs that specifically target cancer cell mutations or characteristics are revolutionizing treatment. For example, *Gleevec*, the first targeted therapy, has dramatically improved survival rates for chronic myeloid leukemia (#CML).

3. **Monoclonal Antibodies**: Often dubbed “biological missiles,” these treatments target specific proteins on cancer cells, allowing for more precise treatment with fewer side effects.

4. **Hematopoietic Stem Cell Transplantation**: This procedure remains one of the most effective treatments for certain types of blood cancer, especially when other treatments fail.

5. **Immunotherapy**: This approach harnesses the body’s immune system to fight cancer. Techniques like CAR-T cell therapy, which modifies a patient’s T cells to attack cancer cells, have shown promising results in treating various hematologic malignancies. China is at the forefront of CAR-T cell therapy research and application, particularly in treating hematologic malignancies. CAR-T therapy involves extracting a patient’s T cells, modifying them to specifically recognize and attack cancer cells. Clinical research and applications in China have shown remarkable effectiveness in treating leukemia, lymphomas, and multiple myeloma. Some studies indicate that patients receiving CAR-T treatment experience significantly higher long-term survival rates and lower recurrence rates. Furthermore, China has made significant progress in the standardization of CAR-T therapy, personalized treatment plans, and the development of technological platforms, enabling more patients to benefit from this innovative treatment.

## Hope for the Future

Countries like India and those in Southeast Asia are rapidly advancing in the field of blood cancer treatment. Collaborative efforts among healthcare professionals, research institutions, and patient advocacy groups are crucial for improving access to cutting-edge therapies. The development of treatment guidelines tailored to the regional context can ensure that patients receive the best possible care.

### Conclusion

Hematologic malignancies are challenging but treatable diseases. Through early diagnosis and the application of innovative therapies, patients can achieve significant improvements in their health and quality of life. As research continues to evolve, the prospect of long-term survival and even cures for blood cancers is becoming increasingly attainable. Empowering patients with knowledge and access to modern treatments is essential to fighting blood cancer effectively in #SoutheastAsia and #India.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#HematologicMalignancies #LeukemiaAwareness #LymphomaResearch #MultipleMyeloma #BloodCancer #CancerResearch #CAR_Therapy #StemCellTransplant #Immunotherapy #TargetedTherapy #MonoclonalAntibodies #CancerTreatment #MedicalAdvancements #CancerSurvivor #HealthcareInnovation #ALL #AML

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago Myeloma

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

Multiple Myeloma

#MultipleMyeloma #CARTtherapy #BloodCancer #CompleteRemission #CART

 

    Multiple Myeloma (MM) is a malignant blood disorder characterized by abnormal proliferation of plasma cells, which causes damage to vital organs. Patients with high-risk cytogenetic abnormalities like 17p deletion, t(4;14) translocation, and t(14;16) translocation face an even worse prognosis. While new drugs like proteasome inhibitors and autologous stem cell transplantation have improved MM treatment outcomes, relapsed/refractory multiple myeloma (RRMM) continues to be a challenge due to its aggressive nature and tendency to relapse. Despite the use of traditional therapies, many patients either fail to respond or cannot tolerate further treatment due to underlying health issues.

    CAR-T cell therapy, a novel immunotherapy that re-engineers the patient’s own T cells to attack cancer cells, has shown remarkable results in RRMM patients. It offers an alternative for patients who have poor tolerance to conventional treatments, presenting a safer and more effective option. In particular, Equecabtagene Autoleucel, a CAR-T therapy targeting the BCMA antigen on myeloma cells, has demonstrated success in treating patients unresponsive to frontline therapies.

### Case Study: High-Risk MM Patient Achieves Complete Remission

A 45-year-old male patient diagnosed with high-risk multiple myeloma in June 2023 sought further treatment at our hospital after failing to respond to chemotherapy. He had a history of coronary artery disease, diabetes, hypertension, and kidney artery stenosis, making traditional therapies less effective and risky.

    Upon evaluation, the patient’s tests indicated κ-type M protein and abnormal free light chains (FLC-κ of 2410.5mg/L). Imaging scans revealed extensive bone damage caused by multiple myeloma. Genetic testing showed high-risk markers including 17p deletion and 1q21 amplification, further complicating his prognosis.

    Given his high-risk status and poor response to standard treatments, the medical team decided to proceed with CAR-T cell therapy using Equecabtagene Autoleucel. After a smooth cell collection and lymphodepletion process, the patient received CAR-T infusion on November 15, 2023.

### Treatment Outcome and Safety

Eight days after infusion, the patient developed a mild fever, indicating cytokine release syndrome (CRS), which was effectively managed with symptomatic treatment. Despite mild kidney dysfunction and temporary blood cell reductions, no severe side effects or neurotoxicities occurred. By day 42, the patient developed a lung infection, which was treated with antibiotics, leading to a full recovery.

    At the one-month follow-up, flow cytometry showed no minimal residual disease (MRD), confirming the patient had achieved complete remission (CR) with MRD negativity. This outcome was particularly significant considering the patient’s failure to respond to previous treatments.

### A Promising Future for High-Risk MM Patients

This case highlights the potential of CAR-T cell therapy, particularly Equecabtagene Autoleucel, in achieving deep remission for high-risk multiple myeloma patients who fail to respond to conventional therapies. With ongoing advancements in biomedical technology and immunotherapy, CAR-T treatments offer hope for RRMM patients, providing longer disease-free survival and improved quality of life.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChinaMedicalAdvances #InnovativeTreatments #Immunotherapy #EquecabtageneAutoleucel #CancerResearch

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago CAR-T

The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.

The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.

目前中美上市的11款CD19和BCMA CAR-T对血液瘤患者的意义

Expert：

**Jing Pan**

**Associate Chief Physician**

**Department of Pediatric Hematology, Beijing Gaobo Hospital**

**Professional Memberships:**

– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association

**Expertise:**

Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.

Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.

潘 静

副主任医师

北京高博医院 小儿血液科

中国抗癌协会小儿肿瘤专业委员会专业委员

中国抗癌协会血液肿瘤专业委员会青年委员

中国医药生物技术协会医药生物技术临床应用专业委员会青年委员

擅长:

目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年，特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗，优化CAR-T治疗过程中的并发症处理，建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后，T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等，发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago CAR-T

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Is CAR-T therapy really a “one-shot cure”?

And how can we ensure that this CAR “drives well and drives long”?

百万抗癌针能“治愈”肿瘤吗?

如何让CAR“开得好，开得久?”

Expert：

**Jing Pan**

**Associate Chief Physician**

**Department of Pediatric Hematology, Beijing Gaobo Hospital**

**Professional Memberships:**

– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association

**Expertise:**

Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.

Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.

潘 静

副主任医师

北京高博医院 小儿血液科

中国抗癌协会小儿肿瘤专业委员会专业委员

中国抗癌协会血液肿瘤专业委员会青年委员

中国医药生物技术协会医药生物技术临床应用专业委员会青年委员

擅长:

目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年，特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗，优化CAR-T治疗过程中的并发症处理，建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后，T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等，发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago Myeloma

Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma

**Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma**

Serum Protein Electrophoresis

#MultipleMyeloma #BloodCancer #SerumProteinElectrophoresis #MM #Mprotein #monoclonalprotein #SPE

As we age, it’s common to experience certain health issues—unexplained anemia, bone pain, fractures, nausea, or abnormal urine changes. Many may dismiss these symptoms as a result of aging, poor diet, or even mild illness. However, such seemingly unrelated signs could indicate a more serious condition: **Multiple Myeloma (MM)**.

**What is Multiple Myeloma (MM)?**

Multiple Myeloma is a type of blood cancer that originates in the bone marrow, where abnormal plasma cells multiply uncontrollably. These malignant cells produce large amounts of a protein called **M-protein** (monoclonal protein), leading to damage in various organs such as the kidneys and bones. The condition is complex, with different patients exhibiting diverse symptoms, often making it challenging to diagnose early. Key factors contributing to MM include genetic mutations and chromosomal changes, alongside abnormalities in the bone marrow microenvironment.

**Why is Early Detection Crucial?**

Over the past few decades, MM cases have steadily increased, particularly among older adults. Delayed diagnosis can result in severe complications, impacting the patient’s quality of life. Due to its subtle onset and wide range of symptoms, many MM patients may see multiple specialists without receiving the correct diagnosis. This makes raising awareness of MM screening critical—early detection can significantly improve survival and quality of life.

One of the most effective tools for early diagnosis is **Serum Protein Electrophoresis (SPE)**—a simple yet powerful lab test that can detect the presence of abnormal proteins, such as M-protein, in the blood.

**How Serum Protein Electrophoresis (SPE) Works**

SPE works by separating the proteins in your blood serum based on their size and electrical charge. Imagine it like children sliding down a playground slide, each going at different speeds depending on their size and shape. Similarly, proteins in the blood move at varying speeds in an electric field. This separation allows us to visualize distinct “protein bands” that represent different proteins like albumin and globulins. For MM patients, the presence of a sharp spike (M-protein) in the **gamma globulin region** serves as a telltale sign of the disease.

This method not only helps in identifying MM but also plays a key role in monitoring disease progression and assessing the effectiveness of treatment. By measuring the quantity of M-protein, doctors can gauge the severity of the disease and tailor therapies accordingly.

**Beyond Multiple Myeloma: Other Uses of SPE**

While SPE is essential for diagnosing MM, it is also a useful tool for identifying other conditions, including **liver diseases**, **kidney disorders**, and **chronic infections**. For example, in patients with liver cirrhosis, SPE often shows an increase in **beta and gamma globulin**, creating a distinctive pattern called a **beta-gamma bridge**. Similarly, kidney disease patients typically exhibit reduced albumin levels. By analyzing these patterns, doctors gain deeper insights into the underlying health issues.

**Other Diagnostic Tools for MM**

In addition to SPE, there are several other lab tests and imaging techniques that can help detect MM. These include **complete blood counts (CBC)**, **kidney function tests**, **calcium levels**, and imaging such as **X-rays** or **MRIs**. Research has shown that combining various tests, such as hemoglobin, globulin, HDL cholesterol, and uric acid, enhances the early detection of MM.

**A Complex Disease with Varied Outcomes**

Though multiple myeloma remains incurable, treatments can significantly extend survival, especially when caught early. If you or someone you know is experiencing unexplained symptoms like persistent anemia, unusual bone pain, or kidney issues, it’s essential to seek evaluation by a hematologist. Timely diagnosis and treatment are critical to improving both prognosis and quality of life.

**Stay informed, stay vigilant, and prioritize early screening** to protect yourself from the silent threat of multiple myeloma.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070 (Https://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com

#MultipleMyeloma #BloodCancer #CancerAwareness #EarlyDiagnosis #SerumProteinElectrophoresis #HealthTips #MMResearch #CancerScreening #BloodTests #HealthyAging #MedicalBreakthrough

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago Hematological Neoplasms

Hematologic Tumors – Detection: Unveiling the Mysteries of the Disease

**Hematologic Tumors** – Detection:

Unveiling the Mysteries of the Disease

#Hematologic #BloodCancer #CancerDetection #Leukemia #Lymphoma #MultipleMyeloma

Hematologic tumors are a group of malignant diseases caused by the abnormal proliferation of blood-forming cells, affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic tumors include leukemia, myelodysplastic syndromes, lymphoma, multiple myeloma, and myeloproliferative neoplasms.

### Causes of Hematologic Tumors

The development of hematologic tumors is highly complex. Key factors include genetic mutations, immune system abnormalities, radiation exposure, contact with harmful chemicals, viral infections, and hereditary factors. Additionally, unhealthy lifestyle habits, prolonged psychological stress, and poor environmental conditions can increase the risk of these diseases.

In recent years, due to global population aging and modern lifestyle changes, the incidence of hematologic tumors has been on the rise. In China, leukemia and lymphoma rank among the top malignant tumors in terms of incidence and mortality. Therefore, early detection and accurate diagnosis of hematologic tumors are crucial for improving patient outcomes.

### Detection Methods for Hematologic Tumors

Since early symptoms of hematologic tumors are often subtle, many patients are diagnosed in the late stages of the disease. Thus, early detection is essential. The medical field has developed a variety of advanced and precise diagnostic methods to detect and confirm hematologic tumors.

#### 1. **Blood Tests**

A complete blood count (CBC) is a fundamental tool for detecting hematologic tumors. By analyzing the quantity and morphology of red blood cells, white blood cells, and platelets, physicians can preliminarily identify abnormalities. For example, leukemia patients often exhibit abnormal increases or decreases in white blood cells, along with immature cells in the bloodstream.

#### 2. **Bone Marrow Biopsy**

Bone marrow biopsy is a key diagnostic method for hematologic tumors. By analyzing the hematopoietic cells from a bone marrow sample, physicians can determine the presence of abnormal or malignant cell proliferation. This procedure not only confirms the type of hematologic tumor but also helps assess disease progression and treatment efficacy.

#### 3. **Flow Cytometry**

Flow cytometry is an efficient method for detecting hematologic tumors. It rapidly analyzes characteristic markers on the surface of cells, helping doctors identify and quantify abnormal cells. It plays an essential role in diagnosing diseases such as leukemia and lymphoma.

#### 4. **Genetic Testing**

Genetic mutations are a critical factor in many hematologic tumors. Genetic testing can reveal the mutation profile within a patient’s cells, enabling doctors to better understand the underlying cause of the disease and formulate personalized treatment plans. With advancements in molecular biology, genetic testing has become a cornerstone of precision medicine.

#### 5. **Imaging Tests**

For certain aggressive hematologic tumors, imaging tests like CT, PET-CT, and MRI help doctors assess the extent and spread of the disease. These techniques are particularly valuable in staging and evaluating the treatment response of lymphomas.

### Conclusion

The detection of hematologic tumors has become increasingly accurate, greatly improving early diagnosis rates and treatment outcomes. By effectively utilizing blood tests, bone marrow biopsies, flow cytometry, genetic testing, and imaging, patients can receive earlier diagnoses and more tailored treatment plans. With continuous advances in medical technology, the cure rates for hematologic tumors are expected to rise, bringing hope for better health to more patients.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp:+8613717959070

（Https://wa.me/+8613717959070）

Email: doctor.huang@globecancer.com

#HematologicCancer #BloodCancer #CancerDetection #LeukemiaAwareness #LymphomaAwareness #MultipleMyeloma #CancerDiagnosis #GeneticTesting #EarlyDetection #FlowCytometry #BoneMarrowBiopsy #CancerResearch #PrecisionMedicine #CancerTreatment #Immunotherapy #Oncology #CancerAwareness #HealthInnovation #MedicalAdvancements #CancerCare

• 1
• 2
• 3
• 4